11/8/26 Bridging the Generational Divide in Rare Disease Clinical Trials: Tailoring Communication to Maximize Recruitment, Retention, and Equity Previous Retention by Design - Keeping Families Engaged for Multi-Year Studies Next Platform and Basket Trials in Rare Disease: What’s Working, What Isn’t, and What It Takes to Scale You Might Also Like Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients. Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales Learning More from Less: Smarter Design and Execution in Rare Disease Trials
11/8/26 Bridging the Generational Divide in Rare Disease Clinical Trials: Tailoring Communication to Maximize Recruitment, Retention, and Equity Previous Retention by Design - Keeping Families Engaged for Multi-Year Studies Next Platform and Basket Trials in Rare Disease: What’s Working, What Isn’t, and What It Takes to Scale You Might Also Like Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients. Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales Learning More from Less: Smarter Design and Execution in Rare Disease Trials
